Managed care rally faces July tests

Health plan stocks have rallied into the summer as managed care regained leadership across healthcare. Recent market data show broad strength across major plans, with $HUM Humana Inc. $375.83 up about 111% over three months, $CNC Centene Corp. $64.77 advancing roughly 92% over the same span, $UNH UnitedHealth Group Incorporated $415.53 climbing about 52%, and $OSCR Oscar Health, Inc. $28.67 adding strong month and year-to-date gains. That is a powerful tailwind, but it also raises the bar ahead of July earnings when the market will judge margins and membership math.

Momentum into catalysts can be fragile. That rhythm showed up in other groups this year, including RLJ Lodging’s Breakout Faces a Summer Test and in manufacturing where earnings mix became the debate in Flex’s July Results Face a Margin and Mix Test. Managed care now faces its own version of that question: do medical-loss ratios stay contained and do membership gains translate into cash flow?

UnitedHealth Group: utilization lens into July 16

UnitedHealth Group ( $UNH UnitedHealth Group Incorporated $415.53 ) reports on July 16. The company’s latest quarter showed a medical cost ratio of 83.9% alongside commentary that Medicare senior membership declined as pricing actions flowed through. Investors will be focused on utilization signals in the commercial and Medicare books and how Optum’s services mix supports margins and cash flow as the year progresses.

With the stock up about 52% over three months, expectations are higher. Any sign that outpatient or pharmacy trend is re-accelerating, or that Medicare attrition is steeper than anticipated, could test sentiment despite diversified earnings drivers.

Humana: growth vs. Star bonus pressure

Humana ( $HUM Humana Inc. $375.83 ) affirmed individual Medicare Advantage membership growth of approximately 25 percent for 2026 and posted a first-quarter Insurance benefit ratio of 89.4 percent, slightly better than management’s guidance. Management also flagged that adjusted 2026 EPS will be lower year over year due to Star Ratings headwinds despite mitigation efforts. That mix of strong unit growth and quality-bonus pressure is the crux of the debate heading into July updates.

If retention remains high and utilization stabilizes, the market may continue to reward the growth case. But if quality bonuses underwhelm or benefit designs compress margins, the stock’s sharp three-month move could be hard to extend.

Centene: Medicaid rate adequacy and health benefits ratio glide path

Centene ( $CNC Centene Corp. $64.77 ) reported a first-quarter health benefits ratio of 87.3 percent, down 20 basis points year over year, and raised 2026 premium and service revenue guidance by $1 billion, anchored in Medicaid. Full-year guidance implies a health benefits ratio range of 90.9% to 91.7%. That keeps the focus on state rate adequacy, medical-cost containment, and Dual Eligible Special Needs Plan integration as redeterminations fade.

Shares are up strongly over three months. The next leg likely depends on whether state rate decisions and mix stabilize the ratio in the guided range while preserving growth.

Oscar Health: marketplace scale meets risk-transfer math

Oscar Health ( $OSCR Oscar Health, Inc. $28.67 ) delivered a first-quarter medical loss ratio of 70.5% with membership of about 3.17 million people. Higher volume and pricing supported top-line growth. Management also noted higher net risk-adjustment transfer accruals. Marketplace profitability depends on pricing discipline and the risk-transfer calculus, especially after a brisk run near one-year highs.

The stock’s strong recent gains set a high bar. Investors may watch retention and risk-adjustment payables for signs the margin improvement is durable once midyear data finalize.

Policy and utilization: variables that can swing margins

The Centers for Medicare and Medicaid Services’ 2026 Medicare Advantage and Part D Rate Announcement projects an expected average change in revenue of about 5% for plans. That increase is partially offset by a risk-model revision and a drag from Star Ratings. For Medicare Advantage-heavy carriers like $UNH UnitedHealth Group Incorporated $415.53 and $HUM Humana Inc. $375.83 , the net effect still depends on each company’s quality scores, bids, and utilization assumptions.

On the cost side, the market is processing whether outpatient visits and pharmacy trend are normalizing. A broad uptick in medical use would pressure benefit ratios and could quickly reset guidance across the group.

July earnings: signals that matter

UnitedHealth: medical cost ratio trajectory, Medicare senior attrition, and Optum’s margin contribution.

Humana: Star Ratings mitigation, retention dynamics, and whether membership growth converts to margin and cash flow.

Centene: state Medicaid rate updates versus guidance, and the impact of D-SNP integration on mix.

Oscar: risk-adjustment payables, retention after rapid membership growth, and whether pricing holds after a strong run.

Across the group, investors may want to monitor whether cost trends stabilize and membership gains convert into cash generation rather than only revenue growth. The momentum creates potential if margins hold, but it also means any guidance trim could unwind part of the rally.